Industry Odisha Bureau, Sep 04: Cipla’s US subsidiary has struck a new oncology partnership. Invagen Pharmaceuticals will license and supply QL2107 domestically. This biosimilar targets pembrolizumab, marketed globally as Keytruda. Cipla will leverage its US commercial presence to market it. The deal strengthens Cipla’s broader oncology-focused portfolio strategy.
QL2107 aims to widen access to advanced cancer therapies. It could also help lower treatment costs for patients. As a pembrolizumab biosimilar, it targets the same therapeutic pathway as Keytruda. This positions Cipla within the growing US biosimilar oncology space. The product remains under development, not yet commercially available.
Qilu Pharmaceutical carries significant responsibility under this arrangement. The company will handle QL2107’s development entirely. Regulatory registration in the US also falls to Qilu. Supply responsibilities rest with Qilu as well. This division lets each partner focus on core strengths.
Cipla’s role centres specifically on commercialisation within the US. The company will use its existing market presence to distribute QL2107. This commercial infrastructure becomes central to eventual product success. Cipla is not involved in QL2107’s manufacturing or development directly. Its contribution lies in navigating the US healthcare marketplace.
Achin Gupta, Cipla’s Managing Director and Global CEO, framed this strategically. He said the partnership reflects confidence in biosimilars’ long-term potential. It supports Cipla’s ambition to build a robust oncology portfolio. This aligns with the company’s broader therapeutic diversification efforts. Oncology remains one focus area within Cipla’s wider generics business.
Qilu’s General Manager, Hanchang Zhang, echoed similar strategic optimism. He described combining R&D and manufacturing strength with Cipla’s reach. Together, both companies aim to deliver an affordable biosimilar option. Zhang emphasised quality alongside affordability as core partnership goals. The collaboration reflects complementary strengths between a Chinese developer and Indian marketer.
Qilu Pharmaceutical brings substantial pharmaceutical development experience to this deal. Founded in 1958, it operates as a vertically integrated Chinese firm. Its pipeline includes more than 50 biosimilars currently. It also maintains over 130 innovative drug programmes. This scale positions Qilu as a credible biosimilar development partner.
Cipla, meanwhile, brings decades of pharmaceutical market experience. Established in 1935, it has built strength across complex generics. Its portfolio spans respiratory, oncology and antiretroviral treatment categories. This partnership extends that oncology focus into biosimilars specifically. It reflects continued diversification within Cipla’s therapeutic strategy.
Ultimately, this partnership illustrates a common industry pattern. Development-stage biosimilar makers increasingly seek established commercial partners. Cipla’s US presence offers Qilu a pathway to market. For Cipla, it adds a promising oncology asset to its pipeline. Whether QL2107 succeeds commercially will depend on regulatory outcomes ahead.
